Investigating the effect of Curcumin on prediabetic individuals

Examining the effect of Curcumin on fasting blood sugar and insulin resistance index in prediabetic individuals

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181022041407N2

Enrollment

Registered

2023-01-28

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes. Abnormal glucose tolerance test

Interventions

Intervention 1: Intervention group: Curcumin tablet daily (contains 500 mg Curcumin and 5 mg Piperine). Intervention 2: Control group: placebo (similar to intervention in shape, size and color).

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Individuals aged 18-70 years Prediabetes status Satisfaction for participation in research project

Exclusion criteria

Exclusion criteria: Using anti diabetic drugs or other drugs which affect on blood sugar such as Thiazide, Glucocorticoids, Anti-psychotics Systemic disorders such as hepatic or renal failure Oral intolerance Using anti-coagulant drugs

Design outcomes

Primary

Measure	Time frame
FBS (Fasting Blood Sugar). Timepoint: Baseline and after 3 months. Method of measurement: Blood sample.;HOMA-IR (Homeostatic Model Assessment for Insulin Resistance). Timepoint: Baseline and after 3 months. Method of measurement: Using formula: (Glucose * insulin)/405.	—

Secondary

Measure	Time frame
CRP, HbA1C, Insulin. Timepoint: Baseline and after 3 months. Method of measurement: Blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Emadzadeh

Mashhad University of Medical Sciences

maryamemadzadeh@yahoo.com+98 51 3841 7403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026